“Benefit” of Routine Ovarian Biopsy during Laparotomy for Diseases of the Female Reproductive Organs

Marek Szymanski1, Radoslaw Janicki1*, Magdalena Czekien2 and Wieslaw Szymanski1

1Department and Clinic of Obstetrics, Female Pathology and Oncological Gynecology, Nicolaus Copernicus University Collegium Medicum in Bydgoszcz, Poland
2Department of Obstetrics and Gynecology, Regional Specialized Hospital in Grudziadz, Poland

Abstract

Background: Ovarian cancer is the most common cause of death among patients diagnosed with reproductive organ cancers in Poland. Despite the progress and continual improvements in diagnostic techniques and methods of cancer treatment, the epidemiology and natural history of ovarian cancer remain largely unchanged. Approximately three quarters of ovarian carcinoma cases are not detected or treated until the third or fourth stage of the disease. The current routine diagnostic procedures include ultrasound examination, biochemistry marker assessments and histopathological evaluations of ovarian tissue to confirm a diagnosis. The preoperative diagnosis of ovarian cancer remains unsatisfactory, and the search for new effective methods has not provided satisfactory results.

Objectives: To determine whether routine biopsy of macroscopically unchanged ovaries provides sufficient benefit.

Material and methods: We conducted a clinical trial involving approximately 1,000 ovaries from which tissue samples were collected during reproductive organ surgeries, and the tissues were examined by a pathologist. Spearman’s rank correlation was used to compare the results statistically.

Results: The results of the histopathological evaluation of macroscopically unchanged ovaries were normal in 99.8% of patients.

Conclusion: In this context, routine biopsy of macroscopically unchanged ovaries does not provide sufficient benefit. Moreover, it may be associated with increases in surgical complications such as bleeding from the biopsy site. Therefore, biopsy of the ovaries during surgery of reproductive organs should not be performed routinely unless cancer is suspected.

Keywords: Ovarian cancer; Biopsy; Laparotomy; Laparoscopy; Staging

Introduction

Ovarian cancer is the most common cause of death among patients diagnosed with reproductive system cancers in Poland and constitutes approximately 25% of all tumours of the female reproductive organs. The International Agency for Research on Cancer (Lyon) as well as the National Cancer Institute (Bethesda, USA) reported approximately 192,000 new cases of ovarian cancer worldwide in 2000, with an estimated 114,000 (59.375%) deaths. Despite the progress and continuous improvements in diagnostic techniques and methods of cancer treatment, the epidemiology and natural history of ovarian cancer remain largely unchanged. The 5-year survival for all ovarian cancers remains between 30% and 40%. As with all tumours, it is extremely important to detect pathological changes during the earliest stages. The detection of early stage disease dramatically affects the outcome, as early intervention can alter the natural history in some cases. Unfortunately, because of the well-described vague and subtle nature of the symptoms, approximately three quarters of ovarian cancer cases are not detected or treated until the third or fourth stage of the disease. Screening techniques, including laboratory examinations, have not been shown to aid the preoperative detection of malignant changes in the adnexa. Presently, preoperative detection of pre-cancerous changes is unrealistic, particularly because a tumour may appear in macroscopically normal ovaries. Histopathological evaluation of ovarian tissue remains the gold-standard technique to confirm a diagnosis of ovarian cancer, but clearly requires adequate tissue samples. For some time, macro- and microscopic evaluations of the ovaries have been suggested at laparotomy/ laparoscopy for conditions other than ovarian disease.

The routine sampling of ovarian tissue during laparotomy for other gynaecological indications is being carried out at some centres but is still controversial.

Objectives

The aims of this study were to retrospectively evaluate the histology of ovarian tissue taken from macroscopically normal ovaries at laparotomy performed for non-malignant changes in female reproductive organs and to assess the potential benefit of this practice.

Materials and Methods

All patients attended the Clinic of Obstetrics, Gynaecology and Oncological Gynaecology, Nicholas Copernicus University in Torun, Collegium Medicum in Bydgoszcz. Between 1998 and 2004, 607 patients underwent laparotomy (511) or laparoscopy (96) for non-malignant changes in the uterus or adnexa. These patients had sections

*Corresponding author: Radoslaw Janicki, Department and Clinic of Obstetrics, Female Pathology and Oncological Gynecology, Nicolaus Copernicus University Collegium Medicum in Bydgoszcz, Poland, Tel: 601671701; E-mail: radek.janicki@gmail.com

Received November 12, 2017; Accepted March 28, 2018; Published March 30, 2018

Citation: Szymanski M, Janicki R, Czekien M, Szymanski W (2018) “Benefit” of Routine Ovarian Biopsy during Laparotomy for Diseases of the Female Reproductive Organs. J Cancer Sci Ther 10: 069-071. doi: 10.4172/1948-5956.1000520

Copyright: © 2018 Szymanski M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
of ovarian tissue collected for histological analysis after full informed consent was obtained from each patient. We have obtained the consent of the bioethical commission. For the statistical analysis, Spearman’s rank correlation was used to compare the results.

Results

At the time of surgery, 75% of the women were aged 31–50 years. The mean age of the patients was 42 years (range 7–77 years). Patients aged 41–50 years comprised the largest age group (320; 53%), followed by those aged 31–40 years (136; 22.4%). Only 84 patients (14%) were older than 50 years (Table 1).

Fifty-two abdominal hysterectomies and four vaginal hysterectomies were performed. Supra-cervical amputation of the uterus was performed in 293 patients (48%), without removal of the adnexa in 280. Uterine myomas were excised from 87 women. In 106 patients (17%), the adnexa were removed (54 right-sided and 52 left-sided). Ovarian cysts were excised from 59 women (11%), nearly twice as often on the left side as on right side. The indications for surgery were uterine myoma in 412 patients (68%), which was confirmed histopathologically, and ovarian changes on pre-surgical screening in 171 patients (29%). The remaining 24 patients were operated on for other reasons.

Macroscopic changes were found in only one ovary in 157 patients (26%) and in both ovaries in only 5 patients (<1%). Tissue segments were collected from both ovaries of 369 patients (62% of the total; 317 laparotomies and 52 laparoscopies), from the right ovary only of 122 patients (20%; 101 laparotomies and 21 laparoscopies), and from the left ovary only of 116 patients (18%; 93 laparotomies and 23 laparoscopies) (Table 2).

Material from macroscopically normal ovary pairs of 369 patients was evaluated, of which 238 sections were histologically reviewed for other reasons.

Discussion

Although this study did not formally assess the complications

### Table 1: Numbers of surgical patients in each age group.

| Patient age group | Number | % |
|-------------------|--------|---|
| ≤ 20              | 10     | 1.6|
| 21-30             | 57     | 9.4|
| 31-40             | 136    | 22.4|
| 41-50             | 320    | 52.7|
| 51-60             | 75     | 12.4|
| >61               | 9      | 1.5|
| Total             | 607    | 100|

### Table 2: Numbers and percentages of patients according to type of surgical procedure.

| Surgical procedure | Number | Final number | % |
|--------------------|--------|--------------|---|
| Supracervical hysterectomy without adnexa | 280 | 293 | 48.3 |
| Supracervical hysterectomy with adnexa | | | |
| Right | 4 | | |
| Left | 9 | | |
| Removal of adnexa | | | |
| Right | 54 | 106 | 17.5 |
| Left | 52 | | |
| Uterine myomectomy | 87 | | 14.3 |
| Hysterectomy without adnexa | | | |
| Abdominal | 52 | 56 | 9.2 |
| Vaginal | 4 | | |
| Removal of ovary cyst | | | |
| Right ovary | 19 | | 9.8 |
| Left ovary | 35 | | |
| Both ovaries | 5 | | |
| Other | 6 | | 0.9 |
| Total | 607 | | 100 |
associated with the sampling of ovarian tissue, such complications have been reported in the literature [2, 26, 27]. In our study alone, the additional costs incurred from histological examination of normal tissue are significant even on a local scale. Therefore, the authors conclude that targeted sampling of abnormal ovaries detected during preoperative screening or laparotomy is the appropriate and correct practice. Routine sampling of normal ovaries is not warranted [1, 3, 14, 20, 27].

Clearly, early detection of ovarian malignancy remains a challenge. This study confirms that other, more focused methods of detection must be developed if the high mortality from this disease is ever to be decreased.

**Conclusion**

There are no benefits to routine ovarian biopsy during surgery for diseases of the female reproductive organs. It does not improve the detection of early stage ovarian cancer and may unnecessarily increase the costs of treatment.

**References**

1. Adamczak R, Szymański M, Szymański W (2001) The usefulness of laparoscopy and laparotomy in the treatment of ovarian tumors. Ginekol Prakt 8: 3-5.
2. Gerber J (2002) Clinical picture of ovarian cancer. In: Markowska J (ed). Gynecological Oncology (1st edn) Wrocław. Urban & Partner.
3. Skręt A, Obrzut B (2002) Surgery in ovarian cancer. In: Markowska J. (ed). Gynecological Oncology (1st edn) Wrocław. Urban & Partner 2002: 797-807.
4. Stelmachów J, Śpiewankiewicz B (2004) Contemporary opportunities for recognition and treatment in oncology gynecology. Ginekol Prakt 12: 13-15.
5. Studd J (1989) Prophylactic oophorectomy. Br J Obst Gynecol 96: 506-509.
6. Tazelaar HD, Bostwick DG, Ballon SC, Hendrickson MR, Kempson RL. (1985) Conservative treatment of borderline ovarian tumors. Obstet Gynecol 66: 417-422.
7. Urban A, Mischczyk L, Jajnika R (2003) Diagnostic and therapeutic problem of oncological gynecology. Conv Onkol 7: 294-300.
8. Berman ML (2003) Future directions in the surgical management of ovarian cancer. Gynecol Oncol 90: 33-39.
9. Li AJ, Karlan BY (2003) Surgical advances in the treatment of ovarian cancer. Hematol Oncol Clin North Am 17: 945-956.
10. Boran N, Tulunay G, Caliskan E, Faruk Köse M, Haberal A (2005) Pregnancy outcomes and menstrual function after fertility sparing surgery for pure ovarian dysgerminomas. Arch Gynecol Obstet 271: 104-108.
11. Chang HJ, Han SH, Lee JR, Jee BC, Lee BI, et al. (2010) Impact of laparoscopic cystectomy on ovarian reserve: serial changes of serum anti-Müllerian hormone levels. Fertil Steril 94: 343-349.
12. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, et al. (2009) Surgical management of borderline ovarian tumors: The role of fertility sparing surgery. Gynecol Oncol 113: 75-82.
13. Szymański M, Socha MW, Szymański W, Kolossa T (2005) Fertility sparing surgery (FSS) in patients with ovarian cancer. Ginekol Prakt 7: 2-7.
14. Mc Hale MT, DiSaia PJ (1999) Fertility-sparing treatment of patients with ovarian cancer. Compr Ther 25: 144-150.
15. Rzepka-Górska I, Błogowska A (2003) Germinal tumors in girls and young women. Ginekol Pol 74: 840-846.
16. Alvarez RM, Vazquez-Vicente D (2015) Fertility sparing treatment in borderline ovarian tumours. Ecancermedicalscience 9: 507.
17. Dimitrios Z, Panagopoulos P, Christodoulaki C (2014) Fertility sparing options with ovarian neoplasms. HJOG 13: 59-66.
18. Morice P, Wicart-Poupe F, Rey A, El-Hassan J, Pautier P, et al. (2001) Results of conservative treatment in epithelial ovarian carcinoma. Cancer 92: 2412-2418.
19. Morice P, Uzan C, Gouy S, Verschaeren C, Haie-Meder C, et al. (2012) Gynaecological cancers in pregnancy. Lancet 379: 558-569.
20. Nezhad FR, Pejovic T, Finger TN, Khali SS (2013) Role of minimally invasive surgery in ovarian cancer. J Minim Invasive Gynecol 20: 754-65.
21. Piłyński K, Szcudrawa A, Basta A (2001) Changes occurring in the ovaries after removal of the uterus. Overview of the drug 58: 805-808.
22. Ranney B, Abu-Ghazaleh S (1977) Future function and fortune of ovarian tissue which is retained in vivo during hysterectomy. Am J Obstet Gynecol 129: 626.
23. Szymański W (2002) Ovarian tumors during pregnancy. In: Markowska J (ed) Gynecological Oncology (1st edn) Wrocław. Urban & Partner.
24. Abascal-Saiz A, Sotillo-Mallo L, de Santiago J, Zapardiel I (2014) Management of borderline ovarian tumours: A comprehensive review of the literature. Ecancermedicalscience 8: 403.
25. O’Neill KE, Cooper AR (2011) The approach to ovarian dermoids in adolescents and young women. J Pediatr Adolesc Gynecol 24: 176-180.
26. Soriano D, Yafet Y, Seidman DS, Goldenberg M, Mashiach S, et al. (1999) Laparoscopy versus laparotomy in the management of adnexal masses during pregnancy. Fertil Steril 71: 955-960.
27. Sobczewski P, Kupryjańczyk J, Śpiewankiewicz B (2015) Borderline ovarian tumors – diagnosis, treatment and follow-up. Curr Gynecol Oncol 13: 234-244.